September 26, 2022

State-run Medicaid insurance, expanded in 2014 as part of the Affordable Care Act, has resulted in decreased metastatic cancer incidence rates as well as decreased overall cancer mortality rates and averted over one thousand deaths due to cancer per year. About 12% of the improvements in cancer mortality were due to decreases in metastatic diagnoses, according to a study to be presented as part of the 2022 ASCO Quality Care Symposium. 

September 26, 2022

A cancer navigation program can reduce overall costs when deployed in collaboration with a statewide Medicare Advantage health plan across a wide range of practice types, according to findings to be presented as part of the 2022 ASCO Quality Care Symposium.  

September 26, 2022

Substituting biosimilars, generics and clinically appropriate lower cost drugs for established, costlier drugs was shown to be an effective way to reduce the total cost of care, by 5% or so, while maintaining the quality of care for patients with cancer. Even small shifts towards lower cost drugs resulted in significant reductions in the total cost of care, according to a study to be presented as part of the 2022 ASCO Quality Care Symposium. 

September 8, 2022

Studies evaluating interventions to reduce the total cost of cancer care and a new analysis of changes in cancer incidence and mortality rates after Medicaid expansion under the Affordable Care Act will be highlighted in the 2022 American Society of Clinical Oncology (ASCO) Quality Care Symposium’s official Press Program. Studies featured in the Press Program are among the nearly 500 abstracts that will be presented at the Symposium.

August 15, 2022

Testing for pathogenic germline variants (PGVs) – genetic changes present from the time of conception, those that have been inherited – can help identify patients at risk for hereditary cancers. The role of PGVs in lung cancer has been underrecognized, largely due to the fact that it is mostly assumed to be caused by environmental factors such as cigarette smoking. A new study of patients with lung cancer, however, found that nearly 15% had PGVs, which means they and their family members are at an increased risk for other types of cancers. The results of the study will be presented during the ASCO Plenary Series session taking place August 16, 2022, at 3:00 PM (ET).  

June 7, 2022

Based on guidance from biomarker screening, patients who are 55 years of age and older with low-grade luminal A-type breast cancer may only need endocrine therapy following breast conserving surgery and could avoid radiation therapy entirely, according to new research findings that will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.

June 6, 2022

Two targeted therapies, dabrafenib (Taflinar®) plus trametinib (Mekinst®), significantly increased the overall response rate compared to the standard-of-care chemotherapy combination of carboplatin plus vincristine in pediatric patients with BRAF V600 mutation-positive low-grade gliomas. Secondary findings showed an improved clinical benefit rate and prolonged progression-free survival for dabrafenib plus trametinib compared to carboplatin plus vincristine, according to new research that will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.

June 5, 2022

The use of panitumumab (Vectibix®) plus mFOLFOX6 significantly improved overall survival in patients with RAS wild-type metastatic colorectal cancer that was classified as left-sided compared to patients who received mFOLFOX6, a standard chemotherapy regimen, plus bevacizumab (Avastin®), a monoclonal antibody, according to a finding that will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.

June 5, 2022

Use of high-dose ifosfamide (Ifex®) was found to be superior for treating recurrent and primary refractory Ewing sarcoma compared to three other standard-of-care treatments that are used for the disease, according to research that will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.

June 5, 2022

The use of autologous stem cell transplant (ASCT) early in the course of treatment showed a significant 21.4-month gain in median progression-free survival in younger, newly diagnosed multiple myeloma patients compared to patients who received chemotherapy without an initial transplant. No overall survival benefit has yet been seen using ASCT early compared to keeping it in reserve.

June 5, 2022

The use of trastuzumab deruxtecan (Enhertu®), a new HER2-targeting antibody-drug conjugate, doubled progression-free survival compared to standard-of-care treatment with conventional chemotherapy. It also significantly improved overall survival for patients with metastatic breast cancers expressing low levels of the HER2 receptor, regardless of hormone receptor status. These practice-changing findings identify a new subset of breast cancer - called HER2-low - and redefine how a large proportion of metastatic patients will be treated. This new research will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.

June 4, 2022

The use of sacituzumab govitecan (Trodelvy®) an antibody-drug conjugate, resulted in longer progression-free survival compared to physician’s choice of chemotherapy in patients who have received many prior therapies and who had hormone-receptor positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer, according to new research to be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.

June 3, 2022

Ibrutinib (Imbruvica™) combined with bendamustine-rituximab improved progression-free survival by 50% for older patients with newly diagnosed mantle cell lymphoma compared to patients who received a placebo plus bendamustine-rituximab, according to new research that will be reported at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.

June 3, 2022

The addition of nimotuzumab to gemcitabine (Gemzar®) increases overall survival in patients with K-Ras wild-type advanced pancreatic cancer, particularly for patients who did not need surgery for obstruction of a pancreatic bile duct, according to new research to be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.

May 26, 2022

With the rapid acceleration of the spread of the COVID-19 virus in the United States in March 2020, telemedicine visits became more common for cancer care. However, in an evaluation of telemedicine inequities in 21 common cancers, there were distinctly lower levels of telemedicine use by Black patients and those who were uninsured, lived in suburban or rural areas, and resided in a neighborhood with low socioeconomic status. The research will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.

Pages